PROTEIN NMB0928 AND USE THEREOF IN PHARMACEUTICAL FORMULATIONS

• Main Authors: CABALLERO MENENDEZ, EVELIN, GUILLEN NIETO, GERARDO E, SARDINAS GARCIA, GRETEL, NIEBLA PEREZ, OLIVIA, GARCIA DIAZ, DARIEN, BETANCOURT NUNEZ, LAZARO, HIRAM, PERERA NEGRIN, YASSER, CASTELLANOS SERRA, LILA, ROSA, PAJON FEYT, ROLANDO, GONZALEZ BLANCO, SONIA
• Format: Patent
• Language: English; French; German
• Published: 27.01.2010
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; TESTING; VINEGAR; WINE

Use of a new vaccine antigen applied as a preventive or therapeutic measure against diseases in general, being such disease of bacterial, viral, cancer related, or other origins. The technical objective that this invention pursues is the development of formulations with the ability to increase the protective spectrum of existing vaccines and hence expanding it against different pathogens. In order to achieve this goal the NMB0928 protein was isolated and identified as a component of outer membrane preparations of Neisseria meningitidis capable of inducing bactericidal activity. Additionally the gene codifying for NMB0928 protein was cloned and expressed, and the said polypeptide was purified and its immunogenicity evaluated in animal models. The sequence data from homologous genes showed, due to the high degree of conservation, its high value as a target antigen of a cross-reactive response when it is presented by different routes. Resultant formulations of this invention are of use in the pharmaceutical industry as vaccine formulations for human use.